Literature DB >> 19710701

Analyses of TET2 mutations in post-myeloproliferative neoplasm acute myeloid leukemias.

L Couronné, E Lippert, J Andrieux, O Kosmider, I Radford-Weiss, D Penther, N Dastugue, F Mugneret, M Lafage, N Gachard, N Nadal, O A Bernard, F Nguyen-Khac.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19710701     DOI： 10.1038/leu.2009.169

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  19 in total

1.  Competing cell clones in myeloproliferative neoplasm.

Authors:  Aref Al-Kali; Srdan Verstovsek; Hagop Kantarjian; Rajyalakshmi Luthra; Jorge Cortes
Journal:  Blood       Date:  2010-12-02       Impact factor: 22.113

2.  JAK2V⁶¹⁷F/TET2 mutations: does the order matter?

Authors:  Elodie Pronier; Cyril Quivoron; Olivier A Bernard; Jean-Luc Villeval
Journal:  Haematologica       Date:  2011-05       Impact factor: 9.941

Review 3.  Molecular aspects of myeloproliferative neoplasms.

Authors:  François Delhommeau; Dorota Jeziorowska; Christophe Marzac; Nicole Casadevall
Journal:  Int J Hematol       Date:  2010-02-27       Impact factor: 2.490

4.  TET2 mutations improve the new European LeukemiaNet risk classification of acute myeloid leukemia: a Cancer and Leukemia Group B study.

Authors:  Klaus H Metzeler; Kati Maharry; Michael D Radmacher; Krzysztof Mrózek; Dean Margeson; Heiko Becker; John Curfman; Kelsi B Holland; Sebastian Schwind; Susan P Whitman; Yue-Zhong Wu; William Blum; Bayard L Powell; Thomas H Carter; Meir Wetzler; Joseph O Moore; Jonathan E Kolitz; Maria R Baer; Andrew J Carroll; Richard A Larson; Michael A Caligiuri; Guido Marcucci; Clara D Bloomfield
Journal:  J Clin Oncol       Date:  2011-02-22       Impact factor: 44.544

5.  Role of TET2 mutations in myeloproliferative neoplasms.

Authors:  Elodie Pronier; François Delhommeau
Journal:  Curr Hematol Malig Rep       Date:  2012-03       Impact factor: 3.952

Review 6.  Concise review: preleukemic stem cells: molecular biology and clinical implications of the precursors to leukemia stem cells.

Authors:  Ashley Pandolfi; Laura Barreyro; Ulrich Steidl
Journal:  Stem Cells Transl Med       Date:  2013-01-24       Impact factor: 6.940

Review 7.  Role of TET2 and ASXL1 mutations in the pathogenesis of myeloproliferative neoplasms.

Authors:  Omar Abdel-Wahab; Ayalew Tefferi; Ross L Levine
Journal:  Hematol Oncol Clin North Am       Date:  2012-08-21       Impact factor: 3.722

8.  Mutation patterns of 16 genes in primary and secondary acute myeloid leukemia (AML) with normal cytogenetics.

Authors:  Marta Fernandez-Mercado; Bon Ham Yip; Andrea Pellagatti; Carwyn Davies; María José Larrayoz; Toshinori Kondo; Cristina Pérez; Sally Killick; Emma-Jane McDonald; María Dolores Odero; Xabier Agirre; Felipe Prósper; María José Calasanz; James S Wainscoat; Jacqueline Boultwood
Journal:  PLoS One       Date:  2012-08-09       Impact factor: 3.240

9.  TET2 Expression in Bone Marrow Mononuclear Cells of Patients with Myelodysplastic Syndromes and Its Clinical Significances.

Authors:  Wei Zhang; Zong-Hong Shao; Rong Fu; Hua-Quan Wang; Li-Juan Li; Jun Wang; Wen Qu; Yong Liang; Guo-Jin Wang; Xiao-Ming Wang; Yuhong Wu; Hong Liu; Jia Song; Jing Guan; Li-Min Xing
Journal:  Cancer Biol Med       Date:  2012-03       Impact factor: 4.248

10.  TET2 mutations in Ph-negative myeloproliferative neoplasms: identification of three novel mutations and relationship with clinical and laboratory findings.

Authors:  Andrea Patriarca; Donatella Colaizzo; Gianluca Tiscia; Raffaele Spadano; Silvia Di Zacomo; Antonio Spadano; Ida Villanova; Maurizio Margaglione; Elvira Grandone; Alfredo Dragani
Journal:  Biomed Res Int       Date:  2013-05-25       Impact factor: 3.411
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.